

## Contents

	<b>Page</b>
Contents	viii
List of Tables	ix
List of Figures	x
List of Abbreviation and Symbols	xv
Chapter	
1. Introduction	1
1.1 Introduction	1
1.2 Review of Literature	2
1.3 Objective of the study	30
2. Materials and Methods	31
3. Results	50
4. Discussion	77
5. Conclusion	88
References	90
Appendix	103
Vitae	106

## List of Tables

<b>Table</b>		<b>Page</b>
1	The chemical classification of NSAIDs	6
2	The pharmacokinetics classification of NSAIDs	7
3	Modified comparison of NSAIDs for their selectivity towards COX-1 and COX-2 using <i>in vitro</i> , <i>in vivo</i> and clinical effects	11
4	The selectivity classification of NSAIDs from COX-2 concept	11
5	General therapeutic dose of coxibs	14
6	Groups of study	32
7	A list of concentrations of stock solution, volume of treated medications	35
8	A summary of the investigation scheme	40
9	A summary of the investigation procedure	41
10	Statistical differences of viability of cells in dose dependent manner	64
11	Statistical differences of viability of cells in time dependent manner	65
12	Statistical differences of ALP activity of cells in dose dependent manner	69
13	Statistical differences of ALP activity of cells in dose dependent manner	70
14	Statistical differences of osteocalcin concentration of cells in dose dependent manner	73
15	Statistical differences of PGE <sub>2</sub> levels of cells in dose dependent manner	76

## List of Figures

Figure		Page
1	Modified cyclooxygenase pathway shows prostaglandin synthase catalyzes the transformation of arachidonic acid (AA) into PGG <sub>2</sub> , as well as the peroxidase activity that transform PGG <sub>2</sub> to PGH <sub>2</sub> , the resource of substrate for the production of a variety of prostanoids	3
2	Modified cyclooxygenase pathway shows COX-1, a constitutively expressed enzyme, and COX-2, an inducible enzyme. Both forms of COX regulate the synthesis of PGs	4
3	Chemical subgroups of NSAIDs	5
4	First generation of COX-2 inhibitors celecoxib (4A) and rofecoxib (4B)	12
5	Second generation of COX-2 inhibitors valdecoxib (5A), parecoxib (5B) and lumiracoxib	12
6	Role of PGs on functions of bone cells (osteoblasts and osteoclasts) and cartilage cells (chondrocyte)	21
7	Scope of study	32
8	MC3T3-E1 seeded on titanium disks, cultivated in a culture medium, treated with medications according to the group of study	33
9	Flow chart of preparation of titanium disks for cell seeding	34
10	Growth curve of MC3T3-E1 on titanium disks cultivated in culture medium treated with fetal bovine serum for 15 days, (a) growth of cells in <i>static</i> (b) <i>log</i> and (c) <i>plateau</i> phases	37
11	An overview of experimental design (experimental phases categorization, NSAIDs treatment schemes and investigation time)	39
12	Demonstrating a gold-palladium coating procedure using a SPI-Module™ Sputter coater (SPI, USA)	42

## List of Figures (Continued)

Figure		Page
13	Demonstrating examination of cells on titanium disks using SEM (JEOL, JSM-5800LV model, Japan)	42
14	Demonstrated examing of cells on a titanium disk using CLSM (Olympus FV300 Japan)	43
15	MTT assay in a96 well plate was measured using a microplate reader under wave length at 562 nm (Biotrak™ II microplate reader, UK)	44
16	An exponential diagram established from a best fit equation of optical density (OD value) and cell numbers	45
17	Growth of MC3T3-E1 on titanium disk and cell culture plate; growth of cells in (a) <i>static</i> , (b) <i>log</i> and (c) <i>plateau</i> phases; levels of growth in a serum free culture medium without treatment in experimental <i>static</i> , <i>log</i> and <i>plateau</i> phases	50
18	Growth of MC3T3-E1 on a titanium disk cultivated in serum free culture medium for 15 days; * = p<0.05 from 24 hr, ** = p<0.05 from 6 day	51
19	Comparisons of growth of MC3T3-E1 on a titanium disk cultivated in experimental <i>static</i> , <i>log</i> and <i>plateau</i> phases in 10% FBS and serum free culture medium; * = p<0.05 , ** = p<0.01	52
20	SEM images of MC3T3-E1 cells on the surface of titanium disks in experimental <i>static</i> phase on treatment day 1 (A) in culture medium with serum and (B) in serum free culture medium. Original magnifications (1) x500, (2) x1000 and (3) x2500	53
21	SEM images of MC3T3-E1 cells on the surface of titanium disks in experimental <i>static</i> phase on treatment day 5 (A) in culture medium with serum and (B) in serum free culture medium. Original magnifications (1) x500, (2) x1000 and (3) x2500	54

## List of Figures (Continued)

Figure		Page
22	SEM images of MC3T3-E1 cells on the surface of titanium disks in experimental <i>log</i> phase on treatment day 1 (A) in culture medium with serum and (B) in serum free culture medium. Original magnifications (1) x500, (2) x1000 and (3) x2500	55
23	SEM images of MC3T3-E1 cells on the surface of titanium disks in experimental <i>log</i> phase on treatment day 5 (A) in culture medium with serum and (B) in serum free culture medium. Original magnifications (1) x500, (2) x1000 and (3) x2500	56
24	SEM images of MC3T3-E1 cells on the surface of titanium disks in experimental <i>plateau</i> phase on treatment day 1 (A) in culture medium with serum and (B) in serum free culture medium. Original magnifications (1) x500, (2) x1000 and (3) x2500	57
25	SEM images of MC3T3-E1 cells on the surface of titanium disks in experimental <i>plateau</i> phase on treatment day 5 (A) in culture medium with serum and (B) in serum free culture medium. Original magnifications (1) x500, (2) x1000 and (3) x2500	58
26	Fluorescence images of MC3T3-E1 cells stained with FDA in experimental <i>static</i> phase on treatment day 5 on the surface of a titanium disk in (A) Groups A, (B) Group C and (C) Group E (original magnifications (1) x100, (2) x200, (3) x500 and (4) x1000)	60
27	An overview of growth of cells during medication treatment in experimental (a) <i>static</i> , (b) <i>log</i> , and (c) <i>plateau</i> phases; * = p<0.05 from without treatment, ** = p<0.01 from without treatment (mean ±SE, n=3)	61

## List of Figures (Continued)

Figure		Page
28	Growth of cells during medication treatment in the experimental <i>static</i> phase; * = p<0.05 from 9.0 $\mu$ M celecoxib, ** = p<0.01 from 9.0 $\mu$ M celecoxib (mean $\pm$ SE, n=3)	63
29	Growth of cells during medication treatment in the experimental <i>log</i> phase; * = p<0.05 from 9.0 $\mu$ M celecoxib, ** = p<0.01 from 9.0 $\mu$ M celecoxib (mean $\pm$ SE, n=3)	63
30	Growth of cells during medication treatment in the experimental <i>plateau</i> phase; * = p<0.05 from 9.0 $\mu$ M celecoxib, ** = p<0.01 from 9.0 $\mu$ M celecoxib (mean $\pm$ SE, n=3)	63
31	An overview of ALP activity of cells during medication treatment in experimental (a) <i>static</i> , (b) <i>log</i> and (c) <i>plateau</i> phases (mean $\pm$ SE, n=3)	67
32	An ALP activity during medication treatment in the experimental <i>static</i> phase (mean $\pm$ SE, n=3)	68
33	An ALP activity during medication treatment in the experimental <i>log</i> phase (mean $\pm$ SE, n=3)	68
34	An ALP activity during medication treatment in the experimental <i>plateau</i> phase (mean $\pm$ SE, n=3)	68
35	Levels of osteocalcin in culture medium of cells in control group on treatment day 5 of experimental <i>static</i> , <i>log</i> and <i>plateau</i> phases; * = p<0.05 from <i>static</i> phase, ** = p<0.05 from <i>log</i> phase (mean $\pm$ SE, n=3)	71
36	Levels of osteocalcin in culture medium on treatment day 5 in the experimental <i>static</i> , <i>log</i> and <i>plateau</i> phases; * = p<0.05 from <i>static</i> phase, ** = p<0.05 from <i>log</i> phase, *** = p<0.01 from <i>log</i> phase (mean $\pm$ SE, n=3)	72

## List of Figures (Continued)

Figure		Page
37	PGE <sub>2</sub> excretion from cell culture in the control group at treatment day 5 in each phase on cell culture plate, and on titanium disk; * = p<0.05 from <i>static</i> phase, ** = p<0.01 from <i>log</i> phase (mean ±SE, n=3)	74
38	Levels of PGE <sub>2</sub> in culture medium on treatment day 5 in each experimental phase, <i>static</i> , <i>log</i> and <i>plateau</i> ; * = p<0.05 from all experimental groups, ** = p<0.01 from all experimental groups, † = p<0.05 from <i>static</i> phase, ‡ = p<0.05 from <i>log</i> phase (mean ±SE, n=3)	75

## List of Abbreviations and Symbols

α-MEM	= Alpha-minimum essential medium
μg	= Microgram
μl	= Microliter
μM	= Micromolar
°C	= Degree celcius
ALP	= Alkaline phosphatase
ANOVA	= One-way analysis of variance
ATCC	= Amerriican Type Culture Collection
BMP	= Bone Morphogenic protein
BMSCs	= Bone marrow stem cells
Cat No.	= Catalog number
CLSM	= Confocal laser scanning microscope
COX	= Cyclooxygenase
COX-1	= Cyclooxygenase-1
COX-2	= Cyclooxygenase-2
cm	= centimeter
d.	= day
DMSO	= Dimethyl sulfoxide
ECM	= Extracellular matrix
ELISA	= enzyme-linked immunosorbent assay
FBS	= Fetal bovine serum
FDA	=Fluorescein diacetate
Fig.	= Figure
g	= gravitation force
g.	= gram
hr.	= hour, hours
L	= Liter



### List of Abbreviations and Symbols (Continued)

M	= Molar
mg.	= Milligram
min	= minutes
ml	= Milliter
mM	= Millimolar
mm.	= millimeter
mol	= mole
MSCs	= Mesenchymal stem cells
MW	= Molecular weight
N	= number
NaOH	= Sodium hydroxide
Nm	= Nanometer
OD	= Optical density
PBS	= Phosphate buffer saline
PGs	= Prostaglandins
PGE <sub>2</sub>	= Prostaglandin E <sub>2</sub>
RIA	= radioimmunoassay
rpm	= Round per minute
RT	= room temperature
s.	= seconds
SD	= Standard deviation
SE	= Standard error
SEM	= Scanning electron microscope
TMB	= Tetramethyl benzidine
Vol	= volume
W/V	= weight by volume